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nivolumab þ ipilimumab significantly prolonged progression-free survival (co-primary end-
point) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC)
and high tumour mutational burden (TMB; 10 mutations/megabase).
Aim: To evaluate patient-reported outcomes (PROs) in this population.
Methods: Disease-related symptoms and general health status were assessed using the vali-
dated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively.
LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-
5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were
analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated
measures (MMRMs) and time to first deterioration/improvement analyses.
Results: In the high TMB population, PRO questionnaire completion rates were w90% at
baseline and >80% for most on-treatment assessments. During treatment, mean changes from
baseline with nivolumab þ ipilimumab showed early, clinically meaningful improvements in
LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related
quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induc-
tion (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with
nivolumab þ ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower
with nivolumab þ ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduc-
tion: 12.7% [95% confidence interval 2.4e22.5]), irrespective of discontinuation. Time to first
deterioration was delayed with nivolumab þ ipilimumab versus chemotherapy across LCSS
and EQ-5D summary measures.
Conclusion: First-line nivolumab þ ipilimumab demonstrated early, sustained improvements
in PROs versus chemotherapy in patients with advanced NSCLC and high TMB.
Clinical trial registration: NCT02477826.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Advanced nonesmall-cell lung cancer (NSCLC) is
associated with substantial symptom burden, which
negatively affects patients’ health-related quality of life
(HRQoL) [1,2]. Together with clinical efficacy evalua-
tions, patient-reported outcome (PRO) data allow a
broader view of treatment benefit by providing infor-
mation collected directly from patients themselves,
including symptoms and health status [3e5]. Nivolu-
mab, an anti-programmed death 1 antibody, and ipili-
mumab, an anti-cytotoxic T-lymphocyte antigen 4
antibody, are immune checkpoint inhibitors with com-
plementary mechanisms of action and are approved for
co-administration in the treatment of several tu-
mours [6]. Nivolumab monotherapy demonstrated anoverall survival (OS) benefit that translated into
improved PROs versus standard of care in phase III
studies in previously treated, advanced squamous [7,8]
and non-squamous [9,10] NSCLC.
Recent results from Part 1 of the CheckMate 227
study (NCT02477826) showed a significant progression-
free survival benefit (co-primary study end-point) with
first-line nivolumab plus ipilimumab versus chemo-
therapy in patients with advanced NSCLC and a high
tumour mutational burden (TMB; 10 mutations/
megabase); no new safety signals were observed with the
combination [11]. Descriptive analyses of OS show
positive trends for OS with nivolumab plus ipilimumab
versus chemotherapy both in patients with high TMB
and low (<10 mutations/megabase) TMB [12]. The
second co-primary end-point of OS with nivolumab plus
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ligand 1 (PD-L1)eselected patients is ongoing. In
CheckMate 227, disease-related symptoms and general
health status were assessed as prespecified exploratory
end-points using validated PRO measures [13e16].
Given the observed relationship between improved
clinical outcomes and improved PROs with nivolumab
monotherapy in previously treated NSCLC, we set out
to evaluate whether the PFS benefit and manageable
safety profile of first-line nivolumab plus ipilimumab
versus chemotherapy in patients with high TMB, cor-
responding to the completed co-primary end-point
population, would similarly translate into a meaningful
benefit in PROs [8,10,11].2. Methods
2.1. Study design
The design of Part 1 of the CheckMate 227 study has
been reported previously (Supplementary Fig. S1) [11].
Briefly, patients with stage IV or recurrent NSCLC not
previously treated with chemotherapy were enrolled.
Those with a PD-L1 expression level of 1% were
randomly assigned (1:1:1) to receive nivolumab (3 mg/kg
intravenously every 2 weeks) plus ipilimumab (1 mg/kg
intravenously every 6 weeks), nivolumab monotherapy,
or chemotherapy, and those with a PD-L1 expression
level of <1% were randomly assigned (1:1:1) to receive
nivolumab plus ipilimumab, nivolumab plus chemo-
therapy, or chemotherapy. Intravenous platinum-
doublet chemotherapy based on tumour histologic
type was given every 3 weeks for up to four cycles. Full
details on the different chemotherapies given, dosing
regimens, and administration for each study arm are
included in the supplementary material (Supplementary
Fig. S1).
This study is being conducted in accordance with the
International Conference on HarmonisationeGood
Clinical Practice guidelines and the Declaration of
Helsinki. An institutional review board or independent
ethics committee at each centre approved the trial pro-
tocol. All patients gave written informed consent. The
Bristol-Myers Squibb policy on data sharing may be
found at https://www.bms.com/researchers-and-
partners/clinical-trials-and-research/disclosure-
commitment.html.2.2. PRO assessments
The PRO assessment schedule is summarised in
Figure 1. PRO assessments at study visits were admin-
istered before treatment. PROs were assessed using two
validated measures, the Lung Cancer Symptom Scale
(LCSS) [13e15] to examine the impact of treatment on
lung cancerespecific symptoms and the EQ-5D [16] toexamine the impact of treatment on general health sta-
tus. The LCSS includes questions addressing six disease-
associated symptoms (anorexia, fatigue, cough, dysp-
noea, haemoptysis and pain) and three global items
(symptom distress, interference with activity level and
HRQoL) [13e15]. For each item, the degree of impair-
ment was scored on a visual analogue scale (VAS; range
0e100). The LCSS average symptom burden index
(ASBI) was calculated as the mean of the six symptom
scores (range 0e100), with higher scores indicating
greater symptom burden. The minimally important
difference (MID), i.e. the smallest change considered
clinically meaningful, was defined as 10 points for the
individual items of the LCSS and LCSS ASBI [17]. We
constructed a LCSS three-item global index (3-IGI) as
the sum of the scores for the three global items (range
0e300), with higher scores representing better HRQoL;
this exploratory end-point has been previously
described [8,10,18]. An MID of 30 points (10% of the
maximum possible score; based on the sum of the 10-
point MIDs for the three global items) was selected
for the LCSS 3-IGI as a reasonable estimate to guide
interpretation in the absence of a formally established
MID. The EQ-5D comprises a VAS of general health
status ranging from 0 (worst imaginable) to 100 (best
imaginable) and a descriptive system based on five di-
mensions of health status: mobility, self-care, usual ac-
tivities, pain/discomfort and anxiety/depression [16].
Each question in the descriptive system has three levels
of response (no problems, some problems, or extreme
problems). The EQ-5D descriptive index responses were
mapped into a single dimension health utility index (UI)
ranging from death (0) to full health (1), with health
states worse than death being possible (<0), by using
utility weights for the UK population [19]. A MID was
defined as 7 points and 0.08 points for the EQ-5D VAS
and UI, respectively [19].
The PROs evaluated as prespecified exploratory end-
points included deterioration rate by week 12 in the
LCSS ASBI; mean scores and mean changes from
baseline in the LCSS ASBI and 3-IGI, their individual
components and the EQ-5D VAS and UI; longitudinal
mixed-effect model repeated measures (MMRMs)
analysis of scores on the LCSS ASBI and 3-IGI, their
individual components and the EQ-5D VAS and UI and
time to first deterioration/improvement in symptoms in
the LCSS ASBI and 3-IGI, all individual components of
the LCSS and the EQ-5D VAS and UI.
2.3. Statistical analysis
The statistical analysis for the prespecified exploratory
PRO end-points was descriptive and did not include
sample size calculation or hypothesis testing.
PRO questionnaire completion rates (on treatment)
corresponded to the proportion of questionnaires
received out of the expected number (i.e. the number of
Fig. 1. Schedule for collection of PRO data. PRO assessments at study visits were administered before treatment. Black solid circles
indicate assessment time points common to both treatment arms up to week 24. aFollow-up visit 1 occurred 35 (7) days from the last
dose or at treatment discontinuation (7 days), if the date of discontinuation was greater than 42 days from the last dose; follow-up visit 2
occurred 80 (7) days from follow-up visit 1. bSurvival follow-up visits occurred approximately every 3 months (7 days) from follow-up
visit 2. LCSS, Lung Cancer Symptom Scale; PRO, patient-reported outcome.
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point). Changes from baseline in PRO scores and mean
PRO scores at each time point were evaluated using
descriptive statistics in the PRO analysis population,
defined as patients with PRO data at baseline and at
least one postbaseline assessment.
MMRM analysis was performed in the PRO analysis
population for longitudinal evaluation of PROs using
data from common on-treatment assessments (every 6
weeks, corresponding to synchronised assessments be-
tween the 2-week nivolumab plus ipilimumab and 3-week
chemotherapy cycles), with baseline PRO score and study
stratification factors (PD-L1 expression level and histol-
ogy) as covariates and change from baseline in score as the
dependent variable. Data to week 42, where both treat-
ment arms had 10 patients, were included in the model.
Disease-related symptom deterioration or improve-
ment was defined as an individual change in score
meeting or exceeding the MID for worsening or
improvement, respectively. For each treatment arm, the
disease-related symptom deterioration rate by 12 weeks
and its corresponding 95% confidence interval (CI) were
calculated using the ClopperePearson method and
included all assessments on and off treatment within 12
weeks of baseline, with the all randomised, high TMB
population in the denominator. Time to first deteriora-
tion/improvement was defined as the time from ran-
domisation until the first deterioration/improvement in
PRO score meeting or exceeding the MID for each
measure. Further details are described in the supple-
mentary material. A stratified Cox proportional hazards
model was used to estimate hazard ratios (HRs) and their
95% CIs; time to deterioration/improvement was esti-
mated using unstratified Kaplan-Meier methodology.Analyses were conducted using SAS software
(version 9.4; SAS Institute, Cary, NC) and were based
on a database lock of 15 March 2018. LCSS and EQ-5D
data analysis and interpretation was limited to common
assessment time points with 10 patients in each treat-
ment group.
3. Results
3.1. Patients
Overall, 583 patients were randomised to nivolumab
plus ipilimumab and 583 to chemotherapy
(Supplementary Fig. S1). The minimum patient follow-
up was 13.0 months. Of randomised patients, 139 pa-
tients assigned to nivolumab plus ipilimumab (135 of
whom were treated) and 160 patients assigned to
chemotherapy (159 of whom were treated) had high
TMB (10 mutations/megabase). Among patients with
high TMB assigned to nivolumab plus ipilimumab or
chemotherapy, 83% (116/139) and 88% (141/160) of
patients, respectively, had baseline and at least one
postbaseline PRO assessment available for LCSS; these
numbers were 83% (115/139) and 89% (142/160) of pa-
tients, respectively, for EQ-5D. Baseline characteristics
for these PRO-evaluable patients were generally
balanced between treatment groups and comparable
with the overall population (Supplementary Table S1).
3.2. Descriptive analyses of on-treatment PROs
LCSS and EQ-5D completion rates among patients with
high TMB were approximately 90% at baseline and
generally remained high, >80% or approaching 80% for
M. Reck et al. / European Journal of Cancer 116 (2019) 137e147 141most on-treatment assessments where 10 patients were
eligible to respond (Supplementary Table S2). Comple-
tion rates were similar in the all randomised population
(Supplementary Table S2).
In patients with high TMB, mean change from
baseline in LCSS ASBI and LCSS 3-IGI scores at
common assessment time points (every 6 weeks) on
treatment are shown in Figure 2A and 2B. With nivo-
lumab plus ipilimumab, improvements were seen from
week 6 and reached clinically meaningful change by
week 12. However, in the chemotherapy group, LCSSFig. 2. Changes from baseline at common assessment time points on
selected individual symptoms: fatigue (C) and dyspnoea (D) in patien
patients with complete data at baseline and at the given assessment time
Common assessment time points across treatment arms are represented
PRO data available for 10 patients in either treatment arm are plotte
plus ipilimumab and chemotherapy, respectively, were as follows LCSS
(183.0e208.6) and 197.6 (185.4e209.8); fatigue, 35.8 (31.2e40.4) and 3
3-IGI, 3-Item Global Index; ASBI, Average Symptom Burden Index; C
minimally important difference; PRO, patient-reported outcome; TMBASBI and LCSS 3-IGI scores showed little change from
baseline over time. Across individual symptoms, a trend
for improvement over time with nivolumab plus ipili-
mumab on treatment was observed for fatigue and
dyspnoea (Figure 2C and 2D), as well as other symp-
toms, with one exception (Supplementary Fig. S2). For
haemoptysis, the symptom score on average was very
low compared with other symptoms, and the mean score
was <10 at baseline; therefore, an improvement of >10
was not possible (Supplementary Fig. S2). The LCSS 3-
IGI index items of global HRQoL and interference withtreatment in LCSS ASBI (A), LCSS 3-IGI (B) and LCSS ASBI
ts with high TMB (10 mutations/megabase). Analysis includes
points. Circles indicate point estimates and bars indicate 95% CIs.
in the figure and denoted on the x-axes; only time points that had
d on the graph. The mean (95% CI) baseline scores for nivolumab
ASBI, 27.7 (24.6e30.8) and 24.8 (22.2e27.5); LCSS 3-IGI, 195.8
6.0 (31.5e40.5); dyspnoea, 28.8 (23.9e33.8) and 24.8 (20.4e29.1).
I, confidence interval; LCSS, Lung Cancer Symptom Scale; MID,
, tumour mutational burden.
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ipilimumab from week 6, which reached clinically
meaningful change by week 12 and were sustained on
treatment; symptom distress also showed improvement
at week 6 that approached or exceeded the MID at most
subsequent common postbaseline assessments
(Supplementary Fig. S2). In the chemotherapy group,
individual component scores generally remained stable
over time.
Mean change from baseline in EQ-5D VAS and EQ-
5D UI scores at common assessment time points on
treatment are shown in Figure 3A and 3B. With nivo-
lumab plus ipilimumab, changes from baseline in EQ-
5D VAS and EQ-5D UI showed rapid (by week 6)
and clinically meaningful (by week 12) improvement,
which was sustained on treatment. For chemotherapy,
the EQ-5D VAS scores were similar to baseline through
week 12, followed by sustained improvement from weekFig. 3. Changes from baseline (A and B) and mean scores (C and D) at
EQ-5D UI, respectively, in patients with high TMB (10 mutations/m
and at the given assessment time points. Circles indicate point estima
across treatment arms are represented in the figure and denoted on t
patients in either treatment arm are plotted on the graph. CI, confide
reported outcome; TMB, tumour mutational burden; UI, utility index18 onwards; the EQ-5D UI scores remained similar to
baseline or appeared to worsen (weeks 30 and 36).
Mean EQ-5D VAS and EQ-5D UI scores were
similar to published data on patients with lung cancer
[19] at baseline and increased over time on treatment in
both arms (Figure 3C and D). Patients treated with
nivolumab plus ipilimumab, but not with chemo-
therapy, reached the general population norm (i.e.
values for the average person in the general population,
82.8 and 0.86, respectively) [20] in EQ-5D VAS and EQ-
5D UI at week 60, and the scores remained at or close to
this level at most subsequent time points.
3.3. Longitudinal MMRM analysis
In the MMRM analysis, differences between treatments
in change from baseline (Figure 4; Supplementary Table
S3) and mean score (Supplementary Table S3) in LCSScommon assessment time points on treatment for EQ-5D VAS and
egabase). Analysis includes patients with complete data at baseline
tes, and bars indicate 95% CIs. Common assessment time points
he x-axes; only time points that had PRO data available for 10
nce interval; MID, minimally important difference; PRO, patient-
; VAS, visual analogue scale.
Fig. 4. LCSS ASBI differences in change from baseline between treatment arms in the overall treatment period in patients with high TMB
(10 mutations/megabase): longitudinal MMRM analysis. This analysis used data from the common assessment time points (every 6
weeks). Delta values may not match the difference in change from baseline between treatment arms owing to rounding. ASBI, Average
Symptom Burden Index; CI, confidence interval; LCSS, Lung Cancer Symptom Scale; LS mean, least squares mean; MMRM, mixed-
effect model repeated measure; TMB, tumour mutational burden.
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plus ipilimumab versus chemotherapy overall and across
individual symptoms, except for haemoptysis, with
treatment differences exceeding or approaching the
MID. Differences in mean changes from baseline in
LCSS 3-IGI favoured nivolumab plus ipilimumab
versus chemotherapy, with the difference being higher
than the MID for the overall score (mean change 27.5
versus 5.1; difference 32.6) and higher than or
approaching the MID for individual items
(Supplementary Table S3). Similarly, differences in EQ-
5D VAS and EQ-5D UI mean scores and changes from
baseline favoured nivolumab plus ipilimumab versus
chemotherapy, although the magnitude of difference
was small for EQ-5D VAS; for EQ-5D UI, differences
were clinically meaningful (difference in least squares
mean change of 0.091; Supplementary Table S3).3.4. Time to first disease-related deterioration/
improvement
A numerically higher proportion of patients treated with
chemotherapy versus nivolumab plus ipilimumab had
disease-related symptom deterioration either on or off
treatment by week 12 (Figure 5A). Absolute risk
reduction was 12.7% (95% CIZ 2.4e22.5). Time to first
deterioration by LCSS ASBI (Figures 5B and 6) and by
LCSS 3-IGI (Figure 6; Supplementary Fig. S3A) was
delayed with nivolumab plus ipilimumab, with HRs
(95% CIs) for nivolumab plus ipilimumab over chemo-
therapy of 0.40 (0.26e0.63) and 0.56 (0.38e0.82),
respectively. Similar delays in deterioration by EQ-5D
VAS and UI were observed (Figure 6; Supplementary
Figs. S3B and S3C). Nivolumab plus ipilimumab
delayed the time to deterioration versus chemotherapyacross individual LCSS ASBI symptoms, except for
haemoptysis; delays were also observed for LCSS 3-IGI
individual items; however, the 95% CI for symptom
distress included no difference (HR Z 1) (Figure 6).
Estimates from the time to first improvement ana-
lyses showed similar patterns in favour of nivolumab
plus ipilimumab (Figure 7 and Supplementary Fig. S4),
although the 95% CIs included no difference (HR Z 1)
for LCSS ASBI individual symptoms of anorexia,
haemoptysis and pain, LCSS 3-IGI (overall and indi-
vidual items) and EQ-5D VAS.4. Discussion
In patients with advanced NSCLC and high TMB, first-
line nivolumab plus ipilimumab provided early and
sustained improvements in PROs versus chemotherapy.
The two PRO instruments used in this study provided
distinct information on the patient experience. Given the
high symptom burden in advanced NSCLC [21], the
assessment of impact on patients’ symptoms provided
by the LCSS ASBI and 3-IGI are particularly relevant.
As a general health status measure, the EQ-5D provides
the ability to evaluate health status of patients in this
study relative to other, non-NSCLC populations and
indicates how changes in health status would be re-
flected in health technology assessments. Descriptive
and longitudinal analyses of LCSS ASBI and 3-IGI
scores on treatment favoured nivolumab plus ipilimu-
mab over chemotherapy. Although study instruments
and the study assessments schedule were designed to
assess lung cancer symptoms and health status rather
than side-effects of treatment, improvements with
nivolumab plus ipilimumab in individual lung cancer
symptoms within the LCSS ASBI, such as fatigue and
Fig. 5. Symptom deterioration by week 12a (A) and time to first disease-related deteriorationb (B) by LCSS ASBI in patients with high
TMB (10 mutations/megabase). aDisease-related symptom deterioration by week 12 defined as a 10-point increase from baseline in
LCSS ASBI at any assessment (on or off-treatment), analysis by ClopperePearson method. Data shown are mean  95% CIs. bAnalysis
by Kaplan-Meier method; symbols represent censored patients (those without a deterioration event were censored at the date of their last
PRO assessment; those with no data or no baseline data were censored at day 1; those with no postbaseline data were censored at day 2).
c95% CI 15.7e30.1. d95% CI 27.6e42.9. ASBI, Average Symptom Burden Index; CI, confidence interval; HR, hazard ratio; LCSS, Lung
Cancer Symptom Scale; NE, not estimable; PRO, patient-reported outcome; TMB, tumour mutational burden.
Fig. 6. Time to first disease-related deterioration for all measures on treatment (common assessments) or follow-up in patients with high
TMB (10 mutations/megabase). 3-IGI, 3-Item Global Index; ASBI, Average Symptom Burden Index; CI, confidence interval; HRQoL,
health-related quality of life; LCSS, Lung Cancer Symptom Scale; TMB, tumour mutational burden; UI, utility index; VAS, visual
analogue scale.
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with immune-related adverse events observed with
immunotherapy regimens. For haemoptysis, which had
a very low symptom score on average compared with
other symptoms, differences in change from baseline
analyses numerically favoured chemotherapy but weresmall in magnitude, and the 95% CI of the estimates
included no change. Findings for patients’ overall health
status measured by EQ-5D UI were similar to those for
LCSS ASBI and 3-IGI. With the EQ-5D VAS, im-
provements were observed in both treatment groups;
however, the improvement seen with chemotherapy
Fig. 7. Time to first improvement for LCSS ASBI (A) and all measures (B) on treatment (common assessments) or follow-up in patients
with high TMB (10 mutations/megabase). 3-IGI, 3-Item Global Index; ASBI, Average Symptom Burden Index; CI, confidence interval;
HR, hazard ratio; HRQoL, health-related quality of life; LCSS, Lung Cancer Symptom Scale; NE, not estimable; TMB, tumour
mutational burden; UI, utility index; VAS, visual analogue scale.
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plete assessments may be attributed to completion of the
doublet chemotherapy induction, with its accompanying
well-known toxicities.
Incorporating information from all available on-
treatment and off-treatment assessments, a lower pro-
portion of patients treated with nivolumab plus ipili-
mumab had symptom deterioration by week 12.
Analyses including common on-treatment and follow-
up PRO data also demonstrated that nivolumab plus
ipilimumab delayed time to first deterioration and
shortened time to improvement across multiple PRO
measures.
Our findings are consistent with previous reports
showing an improved impact on symptom burden and
HRQoL for immunotherapy versus chemotherapy
across first-line [22] and previously treated [8,10,23,24]
NSCLC. Immunotherapies have also shown a similar
trend in other tumour types [25,26]. It should be noted
that it is difficult to compare PRO results across studies
given differences in disease setting and study design.
This caution acknowledged, the results from two studies
in previously treated NSCLC comparing nivolumab
with docetaxel using the LCSS and EQ-5D showed
improvement in symptom burden and health status
[8,10]; however, our results for first-line nivolumab plus
ipilimumab in patients with high TMB suggest a faster
and more clinically meaningful improvement. Recent
studies have evaluated PROs in patients treated with
immunotherapy plus chemotherapy versus chemo-
therapy alone in first-line NSCLC [27,28]; however,
these studies used other PRO measures and assessed
different end-points, making comparisons with our
study difficult. PRO assessment using the LCSS and
EQ-5D is incorporated in the other ongoing cohorts of
CheckMate 227 Part 1, as well as CheckMate 227 Part 2,
which is evaluating first-line nivolumab pluschemotherapy versus chemotherapy; this will provide
additional information on the impact of nivolumab-
based combinations on PROs in patients with
advanced NSCLC.
Interestingly, in our analysis, improvements with
nivolumab plus ipilimumab were observed relatively
early, within the first 12 weeks of treatment, corre-
sponding to the previously reported median time to
objective response in this treatment group (2.7
months) [11]. We therefore speculate that improvement
in disease-specific and generic PROs may serve as an
early indicator for treatment response. Further analyses
are needed to explore the correlation of PRO changes
with tumour response and OS.
Potential reporting biases owing to the open-label
study design may be a limitation of our analysis; how-
ever, two recent studies found no evidence to support
the hypothesis that patients in open-label studies rand-
omised to the experimental arm report better out-
comes [29,30]. Exclusion of data on patients who
discontinued therapy from the on-treatment descriptive
and MMRM results may understate the difference in
HRQoL between the two treatment groups because
patients who progress and discontinue treatment more
quickly in the chemotherapy arm are frequently those
with inferior HRQoL [9]. Although treatment-related
adverse events were measured and reported in the pri-
mary manuscript [11], symptomatic side-effects of
treatment may be underreported by physicians [31,32].
Patients’ assessments of the incidence and bother-
someness of these side-effects were not captured in this
study; instruments and methods designed to focus on
these effects and how they may differ by method of
action (e.g. immunotherapies) are the subject of ongoing
research.
In conclusion, patients treated with nivolumab plus
ipilimumab experienced more rapid, durable and
M. Reck et al. / European Journal of Cancer 116 (2019) 137e147146clinically meaningful improvements in PROs than those
treated with chemotherapy. These results, together with
the demonstrated efficacy and manageable safety profile
previously reported for nivolumab plus ipilimumab in
this study [11], provide further evidence of the benefits
of first-line nivolumab plus ipilimumab in patients with
advanced NSCLC and high TMB.Funding
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